<DOC>
	<DOC>NCT01507077</DOC>
	<brief_summary>The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).</brief_summary>
	<brief_title>ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity</brief_title>
	<detailed_description>This protocol is designed to test the safety and efficacy of a drug called Beloranib (ZGN-440). It is to be tested for its ability to reduce weight in obese female subjects who are of non-childbearing potential. The study will provide information on how much ZGN-440 gets into the blood, how long it stays in the body, and how it affects other biological markers.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Obese but otherwise healthy females Nonchildbearing potential (surgically sterile, postmenopausal, or receiving implanted or injectable contraceptive for at least 3 months) BMI ≥ 30 and ≤ 45 kg/m2 Stable body weight during the past 2 months Use of weight loss agents in the past month History of eating disorder History of type 1 or type 2 diabetes mellitus Current smokers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Obese</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
</DOC>